title: Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.
authors.affiliation: Department of Hematology, UZ Leuven, UZ Gasthuisberg Herestraat 49, 3000, Leuven, Belgium, Vibeke.Vergote@gmail.com.
authors.forename: V
authors.initials: V
authors.lastname: Vergote
authors.forename: D
authors.initials: D
authors.lastname: Dierickx
authors.forename: A
authors.initials: A
authors.lastname: Janssens
authors.forename: G
authors.initials: G
authors.lastname: Verhoef
authors.forename: T
authors.initials: T
authors.lastname: Tousseyn
authors.forename: P
authors.initials: P
authors.lastname: Vandenberghe
authors.forename: P
authors.initials: P
authors.lastname: Wolter
authors.forename: M
authors.initials: M
authors.lastname: Delforge
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017338:Cladribine / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D057176:Compassionate Use Trials; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007943:Leukemia, Hairy Cell / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D020125:Mutation, Missense; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D010091:Oximes / Q000627:therapeutic use*; D017354:Point Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics; D055732:Pulmonary Aspergillosis / Q000209:etiology; D012074:Remission Induction; D000069283:Rituximab; D016879:Salvage Therapy; D013156:Splenectomy
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D007093:Imidazoles; D009363:Neoplasm Proteins; D010091:Oximes; D047428:Protein Kinase Inhibitors; D017338:Cladribine; D000069283:Rituximab; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib